Kornimate/medical-research-clean huggingface dataset:
the inland northwest colon cancer survivor's study

Conditions: Colon Cancer

Summary: the overall purpose of this study was to address the following questions by describing the trajectory of early survivorship in individuals who undergo both surgical and medical management of colon cancer. what are the changes in quality of life, demands of illness, sexual function, and peripheral neuropathy, following curative resection during the first year of treatment and recovery? is there an interaction between exposures to chemotherapy and changes over time in these outcomes?

the population of interest included colon cancer survivors of both sexes, 18 to 90 years of age, who underwent one of two types of surgical resection and who may receive adjuvant chemotherapy. the prospective design with two cohorts representing exposure to chemotherapy (chemotherapy vs. no-chemotherapy) described the changes in quality of life, demands of illness, sexual function, and peripheral neuropathy, which occurred following curative resection. an analysis of the interaction between time (four measurement occasions) and the independent variable of chemotherapy group by mean values of quality of life, sexual function, peripheral neuropathy, and demands of illness addressed the central thesis question. specific aims 1. examine the relationships among quality of life, demands of illness, sexual functioning, and peripheral neuropathy, for the total sample and by chemotherapy group. 2. examine changes within-subjects (four measurement occasions), between-group (chemotherapy, no-chemotherapy) differences, and the interaction between time and chemotherapy group for quality of life, demands of illness, sexual functioning, and peripheral neuropathy across four measurement occasions.

Eligibility criteria:
inclusion criteria: * male or female at least 18 years of age * biopsy proven colon cancer * plan to undergo open, laparoscopic or robotic surgical colectomy. exclusion criteria: * persons with rectal cancer * surgical resection below the rectal sigmoid junction * does not speak or read english * scheduled to receive radiation therapy during the data collection period * diagnosis of metastatic colon cancer (stage iv) * a previous history of cancer diagnosed with the past five years with the exception of early basal cell or squamous skin cancer or early stage melanoma

Keywords: colon cancer folfox laparoscopic colectomy open colectomy robotic colectomy quality of life sexual function peripheral neuropathy demands of illness cancer survivor
inflammatory response after one-lung ventilation according to ventilation methods

Conditions: Lung Cancer

Summary: unlike conventional thoracic surgery performed under general anesthesia with tracheal intubation, non-intubated thoracic surgery with sedation and regional anesthesia has been performed recently. non-intubated thoracic surgery is expected to reduce the postoperative inflammatory changes by maintaining more physiologic status during the operation compared to intubated thoracic surgery. the aim of this study was to compare perioperative immunological changes between intubated and non-intubated thoracic surgery.


Eligibility criteria:
inclusion criteria: * elective video-assisted thoracoscopic surgery (vats) lobectomy * 20 \< age \< 75 * american society of anesthesiologists (asa) classification i\~ii exclusion criteria: * preoperative inflammation (crp\>10ng/㎖, wbc\>10,000/mm3, body temperature \>38℃) * steroid administration within 1 month * hematologic / autoimmune disease * congestive heart failure (nyha class iii\~iv) or significant arrhythmia * severe obstructive / restrictive pulmonary disease * previous history of thoracic surgery * bmi \>28kg/m2 * expected difficult airway
internal jugular vein cross sectional area

Conditions: Central Venous Pressure

Summary: the trendelenburg position is used to distend the central veins, improving both success and safety of vascular cannulation. the purpose of this study is to measure the cross-sectional area of the internal jugular vein (ijv) in three different positions, using surface ultrasound.


Eligibility criteria:
inclusion criteria: * adult medical or surgical icu patients who have preexisting central venous (jugular/subclavian only) catheters. exclusion criteria: * subjects with only a femoral venous catheter. * subjects whose cvp measurement by the indwelling catheter exceeds 20cm of water. * subjects younger than 18 years old. * inability to obtain informed consent from the subject or the subjects authorized representative.

Keywords: cvp us trendelenburg position ultrasound head down tilt
a pharmacist intervention to improve mother and child health

Conditions: Hypertension

Summary: the goal of this clinical trial is to learn if a research pharmacist can improve the health of new mothers and their babies. the main questions it aims to answer are: * will postpartum women who had elevated blood pressure during pregnancy be willing to participate in the study, talk to a pharmacist about their health and the health of their child, and text us their blood pressure measurements? * will contact with the pharmacist improve the health of the mother and/or the child? participants will: * complete a baseline demographic survey, * be given a blood pressure cuff and taught how to use it, * be asked to text us their blood pressure values 2 times per day for 7 days after enrollment, * complete a phone call with a pharmacist discussing their health and the health of their baby, * text us their blood pressure 1 time per day for 3 days 1 month after enrollment, * have a 1 month follow-up phone call with the research pharmacist, and * complete an exit survey to provide feedback about the study.


Eligibility criteria:
inclusion criteria: * biological mother of a baby attending a 1-week to 6-month well-child visit, * received prenatal care at university of iowa hospitals and clinics, * had at least 2 elevated blood pressures (\>= 130 mmhg systolic or \>= 80 mmhg diastolic) during pregnancy, * owns a smartphone exclusion criteria: * arm circumference \> 17 inches, * prisoner status * unable to provide own written informed consent
safety,tolerability and immunogenicity of vaccination with rotateq in healthy infants in india (v260-021)

Conditions: Gastroenteritis; Rotavirus

Summary: to observe the safety, tolerability and immunogenicity of the administration of 3 doses of rotateq in healthy indian infants between 6 weeks through exactly 12 weeks of age at entry.


Eligibility criteria:
inclusion criteria: * age 6 weeks through exactly 12 weeks * healthy infants exclusion criteria: * clinical evidence of active gastrointestinal illness * fever, with a rectal temperature of greater than and equal to thirty eight degree celsius at the time of immunization * history of congenital abdominal disorders, intussusception, or abdominal surgery * history of known prior rotavirus disease * known or suspected impairment of immunological function * prior administration of any rotavirus vaccine * known hypersensitivity to any component of the rotavirus vaccine, e.g. trypsin
post-stroke walking speed and community ambulation conversion study

Conditions: Chronic Stroke

Summary: the purpose of this randomized, controlled study is to collect performance data on the ability of an investigational device designed to digitally deliver rhythmic auditory stimulation to improve walking speed in people who suffered a stroke greater than six (6) months in the past and who are limited in mobility outside the home. the primary outcomes will be the mean change in walking speed (meters per second) and mean percent change in walking speed as determined by a 10-meter walk test after five weeks of intervention and compared between groups.

study participants who take part in this research study will participate in a screening visit, fifteen (15) intervention visits over approximately five weeks and a final closing visit. study participants will be assigned by chance to one of the two study groups. participants will not be able to switch groups once they are assigned. the investigational device includes a mobile device app and sensors that are attached to shoes. headphones and a mobile device are also required to be used and will be provided in this study.

Eligibility criteria:
inclusion criteria: 1. 50 years of age and older 2. equal to or greater than six months post-stroke 3. a comfortable walking speed greater or equal to 0.5 meters per second (m/s), but less than 0.8m/s, as determined by a 10-meter walk test. 4. demonstrates some level of asymmetry in gait exclusion criteria: 1. has a known history of neurologic (excluding stroke) injury 2. has had more than 2 falls in the previous month 3. is enrolled in another walking rehabilitation intervention (e.g., physical therapy) 4. has an external lower limb prosthetic ("artificial limb") 5. has a hearing impairment 6. had orthopedic surgery in the last year 7. has severe aphasia and/or a speech/language disorder 8. has co-morbidities that prevent participation in exercise
early antibiotic discontinuation in fuo

Conditions: Febrile Neutropenia; Hematological Malignancy

Summary: febrile neutropenia requires prompt initiation of broad-spectrum antibiotics, which can be responsible for side-effects and selection of resistance. this study demonstrates the safety of an early discontinuation of empirical treatments, in carefully selected patients presenting with fever of unknown origin.

infections are responsible for significant morbidity and mortality in haematological patients, in particular during chemotherapy-induced neutropenia. guidelines recommend immediate initiation of antibiotic therapy, whose optimal duration is unclear. the primary objective of this study is to evaluate early discontinuation of antibiotic treatment for fever of unknown origin (fuo) in afebrile or febrile neutropenic patients. the secondary objective is to describe the epidemiology of febrile neutropenia (fn) in investigator centre. every episode of fn was prospectively identified. in the first phase of the study, empirical antibiotic therapy of fuo patients was stopped after 48 hours of apyrexia, in accordance with ecil-4 (european conference on infections in leukaemia) recommendations. in the second phase of the study, antibiotics were stopped on day 5 for all fuo patients, regardless of their temperature or their leukocyte count.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * presence of a malignant haematological disease combined with chemotherapy-induced neutropenia (polymorphonuclear neutrophil (pmn) count ≤ 500/mm3) * fever defined by tympanic temperature of ≥38°c for ≥1 hour or a single temperature of ≥38.3°c exclusion criteria: * patients without curative care * chronic neutropenia (pmn≤ 500/mm3 for 3 months or more)
the progress of diabetes mellitus after hms5552 treatment in type 2 diabetes mellitus

Conditions: Type2 Diabetes Mellitus

Summary: at present, there are few studies on the clinical remission rate of diabetes after one year discontinuation of oral hypoglycemic drugs after intensive treatment. hms5552 is a kind of gka hypoglycemic drug. this study intends to observe the clinical remission rate of diabetes mellitus, beta cell function and blood sugar fluctuation of patients with type 2 diabetes mellitus who have been treated with hms5552 for 52w or 28w and whose glucose control is up to the standard.


Eligibility criteria:
inclusion criteria: * complete hms5552 treatment and safety visit; * hba1c \< 8.0% was detected in our laboratory; * researchers judged the stability of glucose control based on the data of subjects'visits during hms5552 treatment and the indicators of our hospital; * subjects are able and willing to monitor peripheral blood sugar and regularity of diet and exercise; * willing to sign written informed consent and abide by the research program. exclusion criteria: * there was a state of illness in the subjects who could not complete the follow-up during the observation period. * the researchers judged that subjects'compliance with hms5552 was affected during treatment.

Keywords: glucokinase activator glucose control
td-1473 long-term safety (lts) ulcerative colitis (uc) study

Conditions: Ulcerative Colitis (UC)

Summary: a 3-year multi-center, long-term safety (lts) study to evaluate the safety and tolerability of td-1473 in subjects with ulcerative colitis who have participated in the maintenance study of protocol 0157

this is a multi-center, long-term safety study to evaluate the safety and tolerability of td-1473 for up to 156 weeks (3 years) + 4 week follow-up in subjects with moderate to severe uc exiting the preceding maintenance study of protocol 0157 (nct03758443).

Eligibility criteria:
inclusion criteria: to be eligible for the study, subjects are required to enter the lts study within 14 days of exiting the maintenance study of protocol 0157 and must meet all the following criteria: * capable of providing informed consent, which must be obtained prior to any study related procedures. * one of the following: * those who demonstrated persistent loss of response (no improvement 8 weeks after meeting loss of response criteria) or * two clinical flares after an episode of loss of response during the maintenance study or * those who have completed the maintenance study and confirmation of clinical remission status results are available * during the study and for 7 days after receiving the last dose of the study drug, females of childbearing potential or men capable of fathering children must agree to use highly effective birth control measures (failure rate \<1% when used consistently and correctly)) or agree to abstain from sexual intercourse. females of childbearing potential must test negative for pregnancy at day 1 * all male subjects must agree to refrain from semen donation during the study and for 7 days after the last dose of study drug. * must be able and willing to adhere to the study visit schedule and comply with other study requirements. exclusion criteria: * has symptoms suggestive of fulminant colitis, megacolon or intestinal perforation * likely to require surgery for uc or other major surgeries * has previously received / is currently receiving prohibited medications * has been diagnosed during protocol 0157 with crohn's disease, other colitis conditions or the subject has a current or past diagnosis of a fistula or abdominal abscess * has endoscopic findings during protocol 0157 of colitis-associated colonic dysplasia (with the exception of subjects with non-colitis associated spontaneous adenomas that have been completely resected) * has clinically significant abnormalities in laboratory evaluations * additional exclusion criteria apply

Keywords: td-1473 janus kinase inhibitor jak inhibitor inflammatory bowel disease ibd ulcerative colitis uc intestinal restriction gut-selective
the effect of low-dose interleukin-2 on the immune landscape of human atherosclerotic plaques at single cell resolution.

Conditions: TIA; Carotid Artery Plaque; Carotid Atherosclerosis

Summary: the goal of this clinical trail is to compare the differences in carotid plaque treg cells' gene signature for activation, proliferation, and suppressive function using scrna-seq in patients treated with il-2 compared to control.

up till now our lab has looked at tregs and immune cells in the blood. the question remains whether low dose il-2 can have the desired effect on tregs in atherosclerotic plaques where they could alter the pathophysiology and potentially clinical outcomes for patients. up until recently, the cellular composition and cell-specific expression patterns of human atherosclerotic plaques remained elusive. however, recent breakthroughs studies using scrna-seq, cite-seq, and single-cell atac-seq on human carotid plaques have offered important insight into plaque composition, cell heterogeneity, and cell-cell interactions giving new perspectives on mechanisms of disease. the next logical stage is to use this new insight and powerful biological tool to assist in drug development for patients. therefore, the aims of the study are: 1. to assess if low dose il-2, given systemically to patients at our proposed dose, can alter tregs in atherosclerotic plaques (the disease tissue) to exhibit a proliferating, activated, and immunosuppressive phenotype 2. to assess if modulating plaque tregs can cause a shift in the plaque immune landscape to a less inflammatory phenotype 3. to study the relationship between plaque and circulating immune cells after systemic immune modulation

Eligibility criteria:
inclusion criteria: * presence of carotid stenosis on either ultrasound or ct scan. * planned to undergo carotid endarterectomy. exclusion criteria: * autoimmune disease * any regular immunosuppressive treatment \[inhaled or topical steroids are permissible\] * modified rankin scale score of ≥4 at screening * known active hepatic disease or alanine aminotransferase (alt) \> 2xuln * severe chronic kidney disease (defined as egfr \< 30 ml/min/1.73m2) * allergy or intolerance to aldesleukin * signs or symptoms of active infection * history of human immunodeficiency virus (hiv), hepatitis b or c * current malignancy requiring active treatment * vaccine within 4 weeks prior to screening or plans for vaccination during study period * women of child-bearing potential and pregnancy * women who are breast-feeding * clinically relevant medical or surgical conditions that, in the opinion of the

Keywords: interleukin-2 il-2 tia carotid stenosis
microsphere localization using pet/mri or pet/ct in patients following radioembolization

Conditions: Liver Neoplasms

Summary: the successful localization of the y90 microspheres by pet/mr and/or pet/ct scans would be a useful tool in individualizing patient care after the radioembolization procedure. the information from a pet/mr or pet/ct scan would allow for early evaluation of the technical success of the procedure.


Eligibility criteria:
inclusion criteria: * participant must successfully complete the mri screening form if receiving an mri * participant must be scheduled to undergo radioembolization for any indication * participant must be ≥ 18 years of age * participant must be able to understand and willing to sign an institutional review board (irb)-approved written informed consent document exclusion criteria: * participant must not have any contraindications to mri scanning * patient must not be pregnant or breastfeeding * if agreeing to mri contrast, participant must not have renal insufficiency (glomerular filtration rate (gfr \< 30 ml/min/1.73 m2) measured within the past 60 days * if agreeing to mri contrast, participant must not be on dialysis * if agreeing to mri contrast, participant must not have had a prior allergic reaction to gadolinium-based contrast agents * pet/mri or pet/ct is not able to be scheduled within 72 hours of radioembolization
validation of a new tsh test

Conditions: Sub-clinical Hypothyroidism; Hypothyroidism; Euthyroidism

Summary: the aim of this research project, which is realised with the partnership of the enterprise siamed'xpress (marseille), is to validate a new tsh diagnostic test in vitro, to allow an earlier screening of hypothyroidism. a serum bank will be conserved in the "centre de biologie sud" ("groupement hospitalier lyon sud"). the serum samples will be assayed locally for the usual medical support to patients and after they will be sent to siamed'xpress (marseille), where they will be assayed with the new diagnostic test. the results obtained from the two techniques will be compared. the validation of this new tsh test represents a major advancement, since it could bring in the future to a therapeutic index which will allow clinicians to treat earlier asymptomatic patients with subclinical hypothyroidism.


Eligibility criteria:
inclusion criteria: 1. subjects more than 18 years old 2. thyroid test planned in the normal health care of patients 3. subject who has been informed about "tsh testing" study with a complete subject information sheet and who has signed a consent form 4. subject covered by the health social system exclusion criteria: 1. subjects with hyperthyroidism (clinical symptoms : weight loss with unaltered appetite, palpitations in the absence of cardio-vascular pathology, unusual and recent nervousness) 2. subject not covered by the health social system 3. subject who already participates to another clinical research study, which might interfere with tsh testing study 4. pregnant, parturient or breastfeeding mother 5. person deprived of freedom by a judicial or administrative decision 6. person under a legal guardianship or unable to consent (mmse score \< 20/30 for the patients for whom this test has been performed).

Keywords: tsh testing sub-clinical hypothyroidism
observational study on the use of iv (intravenous) iron therapy among subjects with iron deficiency anemia

Conditions: Iron Deficiency Anemia (IDA)

Summary: the primary objective of this study is to compare the total costs to sites and payers of administering iv iron over the 30-day observation period for subjects with ida who receive ferric carboxymaltose (fcm) relative to those who receive iron sucrose, iron dextran, and ferumoxytol.

the primary objective of this study is to compare the total costs to sites and payers of administering iv iron over the 30-day observation period for subjects with ida who receive ferric carboxymaltose (fcm) relative to those who receive iron sucrose, iron dextran, and ferumoxytol.

Eligibility criteria:
inclusion criteria: * must present for the first dose of a current cycle of iv treatment for ida * must be over 18 years of age * must be willing and able to provide informed consent, including permission to obtain information from their medical records. * must be able to read and understand english. exclusion criteria: * subjects not diagnosed with ida. * subjects requiring more than one treatment cycle within 30 days. * subjects receiving maintenance iv iron therapy. * subjects treated with iv iron within the 30-day period prior to study enrollment. * subjects who received investigational medication in the six months prior to the study.
interventions to improve hiv care engagement after hospital discharge

Conditions: HIV/AIDS

Summary: a quasi-experitmental study of the efficacy interventions, including additional hiv care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment, in improving hiv care engagement within 30 days after hospital discharge among hiv-infected patients.


Eligibility criteria:
inclusion criteria: * hiv-infected patients hospitalized at thammasat university hospital during the study period exclusion criteria: * the patients who die during admission, are readmitted prior to 30 days after discharge or with incomplete data * readmission episodes of the same enrolled patients during the study period